These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 22533380

  • 1. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.
    Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F.
    Curr Gene Ther; 2012 Jun; 12(3):152-60. PubMed ID: 22533380
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [Abstract] [Full Text] [Related]

  • 3. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.
    Mol Ther; 2017 Nov 01; 25(11):2561-2572. PubMed ID: 28865998
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
    Koo T, Wood MJ.
    Hum Gene Ther; 2013 May 01; 24(5):479-88. PubMed ID: 23521559
    [Abstract] [Full Text] [Related]

  • 5. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B, Wood MJA, Roberts TC.
    RNA Biol; 2021 Jul 01; 18(7):1048-1062. PubMed ID: 33472516
    [Abstract] [Full Text] [Related]

  • 6. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M, Takeshima Y, Nishio H.
    Brain Dev; 2016 Jan 01; 38(1):4-9. PubMed ID: 26094594
    [Abstract] [Full Text] [Related]

  • 7. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y, Yokota T.
    Nucleic Acid Ther; 2014 Feb 01; 24(1):57-68. PubMed ID: 24380394
    [Abstract] [Full Text] [Related]

  • 8. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M, Yokota T.
    Methods Mol Biol; 2023 Feb 01; 2640():313-325. PubMed ID: 36995604
    [Abstract] [Full Text] [Related]

  • 9. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA, Saito T, Duddy W, Takeda S, Yokota T.
    Methods Mol Biol; 2018 Feb 01; 1828():141-150. PubMed ID: 30171539
    [Abstract] [Full Text] [Related]

  • 10. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K, Feng L, Arechavala-Gomeza V, Guglieri M, Straub V, Bushby K, Cirak S, Morgan J, Muntoni F.
    Hum Gene Ther Methods; 2012 Oct 01; 23(5):336-45. PubMed ID: 23075107
    [Abstract] [Full Text] [Related]

  • 11. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A, Aoki Y, Tsoumpra M, Yokota T, Takeda S.
    Methods Mol Biol; 2018 Oct 01; 1828():151-163. PubMed ID: 30171540
    [Abstract] [Full Text] [Related]

  • 12. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ, Graham IR, Malerba A, Dickson G.
    Methods Mol Biol; 2011 Oct 01; 709():153-78. PubMed ID: 21194027
    [Abstract] [Full Text] [Related]

  • 13. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.
    Gene Ther; 2006 Oct 01; 13(19):1373-81. PubMed ID: 16724091
    [Abstract] [Full Text] [Related]

  • 14. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
    Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F.
    Hum Gene Ther; 2007 Sep 01; 18(9):798-810. PubMed ID: 17767400
    [Abstract] [Full Text] [Related]

  • 15. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ, Malerba A, Dickson G.
    Methods Mol Biol; 2012 Sep 01; 867():143-67. PubMed ID: 22454060
    [Abstract] [Full Text] [Related]

  • 16. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R, Yokota T.
    Methods Mol Biol; 2021 Sep 01; 2224():203-214. PubMed ID: 33606217
    [Abstract] [Full Text] [Related]

  • 17. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S, Mizobe Y, Takizawa H, Hara Y, Yokota T, Takeda S, Aoki Y.
    Methods Mol Biol; 2018 Sep 01; 1687():123-141. PubMed ID: 29067660
    [Abstract] [Full Text] [Related]

  • 18. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ.
    Hum Mol Genet; 2009 Nov 15; 18(22):4405-14. PubMed ID: 19692354
    [Abstract] [Full Text] [Related]

  • 19. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, Ferlini A, Bushby K, Straub V, Ricci E, Sewry C, Morgan J, Muntoni F.
    JAMA Neurol; 2014 Jan 15; 71(1):32-40. PubMed ID: 24217213
    [Abstract] [Full Text] [Related]

  • 20. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L, Han G, Gu B, Yin H.
    PLoS One; 2014 Jan 15; 9(11):e111079. PubMed ID: 25365558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.